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Summary
Multiple myeloma (MM) stem cells, proposed to be responsible for the
tumourigenesis, drug resistance and recurrence of this disease, are enriched
in the cancer stem cell-like side population (SP). Cancer testis antigens
(CTA) are attractive targets for immunotherapy because they are widely
expressed in cancers but only in limited types of normal tissues. We
designed a high throughput assay, which allowed simultaneous relative
quantifying expression of 90 CTA genes associated with MM. In the three
MM cell lines tested, six CTA genes were over-expressed in two and LUZP4
and ODF1 were universally up-regulated in all three cell lines. Subsequent
study of primary bone marrow (BM) from eight MM patients and four
healthy donors revealed that 19 CTA genes were up-regulated in SP of MM
compared with mature plasma cells. In contrast, only two CTA genes
showed a moderate increase in SP cells of healthy BM. Furthermore,
knockdown using small interfering RNA (siRNA) revealed that LUZP4
expression is required for colony-forming ability and drug resistance in
MM cells. Our findings indicate that multiple CTA have unique expression
profiles in MM SP, suggesting that CTA may serve as targets for immuno-
therapy that it specific for MM stem cells and which may lead to the long-
term cure of MM.
Keywords: multiple myeloma, cancer testis antigen, side population, high
throughput, quantitative RT-PCR.
Multiple myeloma (MM) is the second most common hae-
matological cancer and represents 10% of all haematopoietic
malignancies in the United States (Jemal et al, 2007). In
2010, the National Cancer Institute reported 20 180 new
cases of MM and 10 650 deaths directly attributed to MM
(Cruz et al, 2011). Despite recent major improvements in
treatment, MM still remains incurable and long-term survival
appears elusive (Chanan-Khan et al, 2010; Borrello, 2012).
Current therapy focuses on killing the myeloma cells with
cytotoxic agents, targeting myeloma cell–specific pathways,
or inhibiting the myeloma-dependent microenvironment.
Although these therapies can lead to initial complete clinical
response, the majority of patients develop relapsed disease
with resistance to these therapies (Munshi et al, 2002; Rich-
ardson et al, 2003). This has led to the hypothesis that mye-
loma stem cell-like cells, which have increased resistance to
many cytotoxic agents and possess self-renewal capacity, may
be responsible for the relapsed disease (Hajek et al, 2013).
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Additional methods are required to eliminate the myeloma
stem cells for the long-term cure of MM.
Cancer testis antigens (CTA) are a promising class of
tumour antigens for T-cell-mediated immunotherapy due to
their limited expression in somatic tissue. An earlier study
demonstrated that CTA could be specifically recognized in
vitro by cytotoxic T-cells (CTLs) in patients with melanoma
(van der Bruggen et al, 1991). Since then, more and more
CTA genes have been characterized and tested as potential
targets for cancer therapy (de Carvalho et al, 2012; Mengus
et al, 2013). Furthermore, another recent study showed that
CTA genes were highly and frequently expressed in glioma
cancer stem cells compared with differentiated cells (Yawata
et al, 2010). Encouraged by previous reports, we hypothe-
sized that CTA genes may have a different expression profile
in myeloma stem cells compared to mature plasma cells
(MPC) and the over-expressed CTA genes may become ideal
targets for immunotherapy for the elimination of myeloma
stem cells.
In present study, based on gene expression data from MM
and normal samples, we designed a high throughput quanti-
tative reverse transcription polymerase chain reaction (qRT-
PCR) assay to simultaneously measure the expression of 90
CTA genes associated with MM. We identified several CTA
genes whose expressions are increased in the MM SP. Fur-
thermore, we found that one of those up-regulated CTA
genes, LUZP4, is required for colony forming and drug resis-
tance in MM cells. These findings will lead to the develop-
ment of new CTL-mediated therapies by targeting these CTA
genes, for the benefit of MM patients.
Material and methods
Cell cultures and reagents
Multiple myeloma cell lines RPMI8226, MM1S and U266
were purchased from the American Type Culture Collection
(ATCC; Manassas, VA, USA). Cells were grown in RPMI
1640 medium (Life Technologies, Grand Island, NY, USA)
with 10% fetal bovine serum (FBS; Atlanta Biologicals,
Atlanta, GA, USA), 100 u/ml penicillin and 100 lg/ml strep-
tomycin (Thermo Fisher Scientific, Houston, TX, USA), as
previously reported (Wen et al, 2011).
Bone marrow (BM) aspirates were collected from eight
MM patients and four healthy donors under a protocol
approved by the Houston Methodist Research Institute and
informed consent was obtained, in compliance with the Dec-
laration of Helsinki. Primary cells were purified from freshly
isolated BM by Ficoll (MP Biomedicals, Solon, OH, USA)
density sedimentation. Cells were cultured in RPMI 1640
medium containing 10% FBS, 100 u/ml penicillin, 100 lg/ml
streptomycin and 2 mmol/l-glutamine, and maintained at
37°C in 5% CO2.
All chemicals, unless otherwise stated, were purchased
from Sigma-Aldrich Co. (St. Louis, MO, USA).
SP analysis and cell sorting by flow cytometry
To identify the SP in MM cell lines, cells were seeded at
05 9 106 cells/ml in a T75 flask for 3 d (72 h after seeding)
in RPMI 1640 medium with 10% FBS, supplemented with
100 u/ml penicillin and 100 lg/ml streptomycin. Cells were
harvested and washed in pre-warmed RPMI 1640 medium
with 2% FBS and 10 mmol/l HEPES buffer, and then resus-
pended at a concentration 1 9 106 cells/ml in RPMI 1640
medium with 2% FBS and 10 mmol/l HEPES. Hoechst
33342 water solution (1 mg/ml) was then added to make a
final concentration of 5 lg/ml followed by incubation in a
water bath at 37°C for 90 min with shaking every 15 min.
Immediately after incubation, the samples were put on ice to
stop dye efflux and washed with ice-cold Hank’s balanced
salt solution (HBSS) containing 2% FBS and 10 mmol/l HE-
PES. Subsequently, Hoechst-labelled cells were stained with
CD138-PE monoclonal antibody (BD Biosciences, San Jose,
CA, USA) for 15 min on ice.
To identify the SP in primary samples, cells were har-
vested and washed in pre-warmed RPMI 1640 medium with
2% FBS and 10 mmol/l HEPES buffer. SP staining was per-
formed as for the cell lines.
Cells were then analysed using FACS Aria (Becton Dickin-
son, San Jose, CA, USA). The Hoechst 33342 dye was excited
at 357 nm and its fluorescent emission was measured at
Hoechst blue fluorescence and Hoechst red fluorescence. SP
cells and mature plasma cells (i.e., CD138-positive non-SP
cells) were then sorted accordingly (Fig 1).
Aldefluor assay by flow cytometry
Aldefluor assay was performed according to the manufac-
turer’s instruction (Stem Cell Technologies, Vancouver, BC,
Canada). The aldehyde dehydrogenase (ALDH) high and low
populations of RPMI8226 cells were analysed and sorted with
the FACS Aria.
cDNA synthesis
cDNA from sorted cells was synthesized with the WT-Ova-
tion RNA Amplification System (Nugen, San Carlos, CA,
USA) according to the user’s guide. The cDNA concentration
was estimated using the NanoDrop ND-1000 spectrophotom-
eter (Thermo Scientific, Wilmington, DE, USA).
CTA gene selection
Cancer testis antigens expression in various types of cancers
should be different. In order to identify CTA signatures in
MM among different stage MM patients, we used the open
access microarray database: Mayo Clinic MM Microarray. This
database was established by analysing BM samples of 91 new,
23 smouldering and 26 relapsed MM patients from MM
research consortium (MMRC, http://www.broadinstitute.org/
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mmgp/home). Then, we integrated this database with the CTA
gene bank database (http://www.cta.lncc.br/) to specifically
study the expression of CTA genes in MM patients and
identified 90 CTA genes expressed by the majority of MM
patients (Fig 2A).
Primers and qRT-PCR
We designed primers for these 90 CTA and 5 housekeeping
genes (data not shown) using Primer 3 software and selected
those that contained at least 1 exon-exon junction to reduce
the genomic DNA contamination. One pair of primers for
each gene was added to each well of a 96-well plate to form
the assay, comprising 90-CTA genes and 5 housekeeping
genes, and one well as a blank control without any primer.
qRT-PCR analysis of the gene expression was then performed
using RT2-SYBR Green PCR Master Mix (Qiagen, Valencia,
CA, USA) with 40 cycles of 15 s at 95°C and 1 min at 58°C
on an ABI 7500 Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA). Fluorescence data were collected at
58°C after each cycle. After the final cycle, melting curve
analysis of all samples was conducted within the range of
58–95°C. The specificity of the PCR products was verified by
the targeted product size using gel electrophoresis and melt-
ing curve analysis. The threshold cycle and 2DDCt method
were used for calculating the relative amount of the target
RNA using the average of the five house-keeping genes as
internal control, according to user’s manual. The experi-
ments were repeated in triplicate.
Immunoglobulin heavy chain (IGH) gene rearrangement
analysis
DNA was isolated from cells using the QIAmp system (Qia-
gen). The concentration of DNA was estimated using the
NanoDrop ND-1000 spectrophotometer. DNA quality was
assessed using Agilent 2100 Bioanalyser (Agilent Technolo-
gies, Santa Clara, CA, USA). PCR primer sequences for
IGHV gene framework region 3 (FR3) were designed as pre-
viously reported (Kummalue et al, 2010). PCR of the IGH
genes to assess clonality used the BIOMED-2 system. Master
mixes were purchased from Invivoscribe Technologies (San
(A)
(B)
(C)
Fig 1. Side population in primary MM BM
sample. (A) Primary MM BM sample was sub-
jected to Hoechst 33 342 SP staining. The SP
and non-SP (NSP) are shown. (B) SP and NSP
populations were analysed for CD138 expres-
sion. (C) IGH rearrangement assay was per-
formed in SP and MPC (NSP/CD138+). The
experiments were repeated three times, and
representative results are shown. MM, multiple
myeloma; BM, bone marrow; SP, side popula-
tion; NSP, non-SP; MPC, mature plasma cells.
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Diego, CA, USA), and the PCR was done as per manufac-
turer’s instructions and used HotStart Taq DNA polymerase
(Qiagen) (Burack et al, 2010).
Immunofluorescence
SP and non-SP (NSP) cells were sorted with Hoechst
33342 staining. After washing, cells were resuspended in
phosphate-buffered saline (PBS) and transferred to a cover-
slip coated with poly-L-lysine. After a 1-h incubation at
room temperature, excess cell suspension was removed.
Cells were washed, fixed, blocked with PBS containing
01% bovine serum albumin, and incubated with primary
anti-AURKA antibody (Thermo Fisher Scientific) for 1 h.
Subsequently, cells were washed with PBS and incubated
with TXRed-labelled secondary antibody. After washing,
coverslips were mounted on slides in fluorescent mounting
medium containing 4’,6-diamidino-2-phenylindole (DAPI)
(ProLong antifade reagent with DAPI; Invitrogen, Carlsbad,
CA, USA). Fluorescence was detected using an Olympus
microscope and images were acquired using Cellsens
Dimension software.
SiRNA knock down
LUZP4 gene siRNA and scrambled siRNA (Santa Cruz Bio-
technology, Dallas, TX, USA) were used at 100 nmol/l to
transfect RPMI8226 cells using Lipofectamine RNAiMAX
(Invitrogen), as previously reported (Wen et al, 2008).
Knockdown efficiency of siRNAs was confirmed by Western
blot analysis.
Western blotting
Cell lysates were prepared and analysed by Western blot as
described previously. The membrane was probed with anti-
body to LUZP4 (Santa Cruz Biotechnology). After detection,
the membrane was completely stripped and ACTB (b-actin)
was used as loading control (Wen et al, 2008).
Cell colony assay
A soft agar colony assay was performed as previously reported
(Wen et al, 2011). Briefly, 15 ml base agar layers of 06% aga-
rose were prepared in 35 mm dishes by combining equal vol-
umes of 12% low melting temperature agarose (Thermo
Fisher Scientific) and 29 RPMI 1640 medium + 20%
FBS + 29 antibiotics. Next, 5 9 103 cells were resuspended in
075 ml 29 RPMI 1640 medium + 20% FBS + 29 antibiotics
and mixed with 075 ml volumes of 06% agar, then immedi-
ately plated on top of base agar. Complete medium was added
on the top and changed twice a week. After 2 weeks, dishes
were stained with methylene blue, pictures were taken under a
phase contrast microscope, and colony number was counted.
Flow cytometric analysis of apoptosis
Cells were treated with arsenic trioxide (Sigma-Aldrich Co.)
or Bortezomib (Millennium Pharmaceuticals, Cambridge,
MA, USA) for 24 h. Dual staining with Annexin V-fluores-
cein isothiocyanate (FITC) and PI (Propidium iodide) (Bec-
ton Dickinson) was used to detect apoptosis according to the
manufacturer’s instructions as previously reported (Wen
et al, 2008, 2010).
Statistical analysis
Statistical analysis was conducted with the SPSS 10 SPSS
Inc., Chicago, IL, USA), using t-test or 1-way analysis of var-
iance (ANOVA) where appropriate.
Results
SP cells from myeloma patients containing clonal
population
The flow cytometric analysis revealed that in primary MM
patient BM, SP cells are CD138-negative and NSP cells are
CD138+ (Fig 1A, B). Immunoglobulin heavy chain (IGH)
(A) (B)
Fig 2. Design of the MM-specific CTA gene
high throughput qRT-PCR Assay. (A) Cancer
testis antigen (CTA) gene expression data from
Mayo Clinic multiple myeloma (MM) expres-
sion array was compared among four groups:
new MM patients (NMM), smouldering MM
(SMM), relapsed MM (RMM) and normal
donors by 1-way ANOVA. If the fold change was
>2 (MM: normal) and P value < 005, the gene
was defined as an abnormal up-regulated gene.
(B) Highly expressed CTA genes in NMM,
SMM, and RMM groups compared with
healthy donor are shown.
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rearrangement study showed that SP and MPC from mye-
loma patients possess the identical IGH rearrangement pat-
tern (Fig 1C). This result indicates that the SP of these
patients contains myeloma stem cells that are of same cell
origin of the mature neoplastic plasma cells.
MM-CTA were enriched in SP in MM cell lines
With the strategy shown in Fig 2A, we designed the MM-
specific CTA gene assay composed of 90 CTA genes and 5
housekeeping genes. Among these 90 CTA genes, 5 genes
were up-regulated in the new MM patient and 4 genes were
up-regulated in the patient with smouldering MM. Futher-
more, 17 CTA genes were up-regulated in relapsed MM
patient, compared with normal control (Fig 2B). The expres-
sion levels as well as the ratio to normal control in relapsed
MM, smouldering MM, and new MM are shown in Table I.
To test if CTA gene expression is enriched in MM SP, we
investigated the CTA expression profile in various myeloma
cell lines and primary samples. We collected SP and MPC,
respectively, from MM cells lines including RPMI8226,
MM1S and U266. Using a threshold of >2-fold change for
genes expression (SP: MPC) and P value < 005 after t-test,
16 CTA genes were up-regulated in RPMI8226 (Fig 3A), 13
CTA genes in MM1S (Fig 3B) and 11 CTA genes in U266
cell line (Fig 3C). Of note, among these genes, GAGE12F,
MAGEA4, MAGEA5, SSX1, and TOP2A genes showed over-
lap in 2 of 3 cell lines, and LUZP4 and ODF1 were univer-
sally up-regulated in all 3 MM cell lines. Furthermore,
Immunofluorescence membrane staining with anti-CTA anti-
gen AURKA antibody was performed. In agreement with our
PCR data, the AURKA antibody stain showed higher
membrane expression in SP cells than in MPC (Figure S1).
MM-CTA were enriched in SP in MM BM samples
We further extended our study to primary MM cells. Nine-
teen CTA genes were significantly up-regulated in SP (fold
change >2 compared with MPC, P < 005, t-test); Fig 4A.
Interestingly, AURKA, DDX43, FANCI, MAGEA3, TEX14,
and LUZP4 were also identified as up-regulated genes in the
SP of at least 1 MM cell line. In addition, 3 CTA genes
(AKAP4, MAGEA3, and SSX2) and 7 genes (ANKRD45,
FANCI, LUZP4, MAGEA12, MAGEB3, RRM2, and TEX14)
were over-expressed by the SP of 8/8 and 7/8 MM patients,
respectively (Table II). The detailed information for MM
patients and fold-change of CTA gene in each patient are
shown in Tables SI and SII, respectively.
In contrast to MM BM, only 2 CTA genes, DUT and
KDM5B (JARID1B), showed moderate increase (22– and
45-fold, respectively) in the SP of normal BM compared
with MPC (Fig 4B). Of interest, these 2 genes were not
up-regulated in the SP of MM patients. Additionally, except
for AKAP4 (395-fold), CFLAR (293-fold), HIST1H2BG
(224-fold), MAGEB2 (418-fold) and MAGEB3 (397-fold),
the expression level of 19 up-regulated CTA genes in SP
of MM BM was more than 5 times higher than that in SP of
normal BM control (Fig 4C).
It should be noted that the SP cells in the myeloma
patients include both cancer stem cells and normal haemato-
poietic stem cells (HSC) while the SP cells in normal samples
contain only normal HSC (Morita et al, 2006; Golebiewska
Table I. Up-regulated cancer testis antigen (CTA) genes in relapsed multiple myeloma (MM) patients and their expression level in normal sam-
ples, new MM, smouldering MM and relapsed MM. The relative expression level compared with normal and the p value of one-way ANOVA test
among different groups is also listed. RMM, relapsed multiple myeloma patients; SMM, smouldering multiple myeloma patients; NMM, new
multiple myeloma patients.
Gene symbol
Average
of Normal
Average
of RMM RMM/Normal P value
Average
of SMM SMM/Normal P Value
Average
of NMM NMM/Normal P Value
TSPY1 131 14417 10972 00153 27917 212 09802 459 350 09482
CTAG2 100 3710 3710 00085 25458 255 09114 842 842 05272
CTAG1B 142 2810 1985 00071 27200 192 08962 724 511 04917
MAGEA6 1093 13044 1194 00013 216263 198 07747 6496 594 00890
SSX2 101 855 845 00189 12571 124 01563 211 208 06910
XAGE1 758 3604 476 00019 119171 157 06385 2091 276 00893
MORC1 391 1700 435 00029 75021 192 04167 1160 297 00411
MAGEA3 4813 18584 386 00019 520454 108 09301 10798 224 01143
SSX1 1689 5074 300 00040 165313 098 09699 2528 150 02981
MAGEA5 331 873 264 00010 41242 125 0621 467 141 03306
NOL4 3795 9646 254 00331 767538 202 01651 8143 215 00666
AKAP4 1386 3380 244 00026 448713 324 ≤00001 3475 251 00003
MAGEA4 1403 3362 240 00110 162088 116 07799 1881 134 04689
MAGEA9 2788 6135 220 ≤00001 372521 134 01752 4594 165 00023
MAGEC1 4681 10180 217 00392 950188 203 00764 11294 241 00044
TTK 941 2015 214 00177 111225 118 07063 1338 142 03062
MAGEB4 606 1243 205 00245 140083 231 00062 876 145 02672
Cancer Testis Antigen Genes in Multiple Myeloma Side Population
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et al, 2011). Thus, the differences of CTA expression between
the SP cells of myeloma patients and controls are most prob-
ably due to the increased expression of CTA genes of cancer
stem cells within the SP cells of myeloma patients.
All these results suggested that CTA have unique expres-
sion profiles in the SP of MM cells, suggesting that CTA may
serve as targets for immunotherapy that is specific for MM
stem cells, which may lead to the long term cure of MM.
LUZP4 gene expression is required for colony formation
and drug resistance
To explore the function of the gene LUZP4, which was uni-
versally up-regulated in SP of MM cell lines and primary
MM BM, we used siRNA to knockdown gene expression and
the efficiency was confirmed by Western blot (Fig 5A). Given
its up-regulated expression level in MM stem cells, which
play a critical role in tumour development, disease recur-
rence, resistance and chemotherapy (Huff & Matsui, 2008;
Matsui et al, 2008; Brennan & Matsui, 2009; Ghosh & Mat-
sui, 2009; Jakubikova et al, 2011; Paino et al, 2012), we
hypothesized that the function of LUZP4 may be related to
colony forming ability and drug resistance. Firstly, the
LUZP4 siRNA knocked-down U266 cells and control cells
were grown on agar for 2 weeks: the results showed that
LUZP4 knocked-down cells formed fewer colonies compared
to control cells. Next, we treated the LUZP4 knocked-down
U266 cells with arsenic trioxide and bortezomib for 24 h and
the results showed that LUZP4 knocked-down U266 cells
were more sensitive to chemotherapy.
(A) (B) (C)
Fig 3. Up-regulated CTA genes in the SP of MM cell lines compared with MPC. SP and MPC cells were sorted from three MM cell lines and
qRT-PCR-based CTA gene assay was carried out. Up-regulated CTA genes in SP (fold change >2 compared with MPC cells, P < 005 after t-test)
are shown. Data are presented as mean  standard deviation of three independent experiments after normalizing the data to the MPC. The flow
cytometric analysis of SP cells in each cell line is shown as inset. (A) MM cell line RPMI8226. (B) MM cell line MM1S. (C) MM cell line U266.
CTA, cancer testis antigen; MM, multiple myeloma; BM, bone marrow; SP, side population; MPC, mature plasma cells.
(A) (B) (C)
Fig 4. Up-regulated CTA genes in the SP of primary MM and healthy donor BM compared with MPC. SP and MPC were sorted out from BM
of MM and healthy donors and qRT-PCR based CTA gene assay was carried out. (A) Up-regulated CTA genes in 8 MM patient SP cells are
shown (fold change >2 compared with MPC, P < 005 after t-test). Data are presented as mean of eight MM samples (each has tripli-
cates)  standard deviation (SD) after normalizing the data to the MPC. The flow cytometric analysis of SP cells is shown as inset. (B) Up-regu-
lated CTA genes in four healthy donor SP cells are shown (fold change >2 compared with MPC, P < 005 after t-test). Data are presented as
mean of four control samples (each has triplicates)  SD after normalizing the data to the MPC. The flow cytometric analysis of SP cells is
shown as inset. (C) The up-regulated CTA genes in SP of primary MM BM have much lower expression level in SP of healthy donor BM. CTA,
cancer testis antigen; MM, multiple myeloma; BM, bone marrow; SP, side population; MPC, mature plasma cells.
J. Wen et al
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Discussion
Our results have indicated that certain CTA genes (e.g., AU-
RKA, DDX43, FANCI, MAGEA3, TEX14 and LUZP4) are up-
regulated in both SP cells of the majority of MM cell lines
and primary marrow samples from MM patients compared
to the mature myeloma cells. This finding indicates that up-
regulation of CTA genes is a common feature for myeloma
cells with stem cell features. This is in accordance with previ-
ous reports showing that enhanced expression of CTA genes
in glioma stem cells and that CTA genes promoters may be
tightly regulated by methylations and the methylation levels
in promoter regions in cancer stem cells are lower than that
in differentiated cells (Yawata et al, 2010). This mechanism
may have contributed to the up-regulation of CTA in cancer
stem cells in general and in myeloma stem cells in our study.
In this study, we used SP cells identified by flow cytome-
try, based on the unique property of stem cells, which pump
out Hoechst 33342 dye due to their high expression of ATP
binding cassette transporters, to identify myeloma stem cells
in MM. This is because studies have demonstrated that SP
cells exhibited clonogenic and tumourigenic potential in MM
(Jakubikova et al, 2011; Ikegame et al, 2012). We did not use
surface markers, another commonly used approach to study
cancer stem cells, because the surface marker phenotype for
myeloma stem cells remains controversial (Yaccoby &
Epstein, 1999; Matsui et al, 2008; Jakubikova et al, 2011).
Similar to the previous study (Jakubikova et al, 2011), we
demonstrated an identical IGH gene rearrangement pattern
in the SP cells and mature neoplastic plasma cells (Fig 1),
confirming that our methodology is adequate to identify the
myeloma stem cells from marrow samples of myeloma
patients. In contrast, clonal IGH rearrangement was absent
in the SP and mature plasma cells of controls when using an
identical approach, indicating a lack of clonal populations
(data not shown). Additionally, we used another function
assay, ALDEFLUOR, for identifying and isolating stem cells
of a myeloma cell line (RPMI8226) based on the high
expression of aldehyde dehydrogenase of stem cells (Matsui
et al, 2008; Brennan et al, 2010). The stem cells isolated
using this functional assay showed similarly elevated CTA
expression as isolated by SP cells, confirming that the overex-
pression of CTA is unique character of myeloma stem cells
(Figure S2).
Of the CTA genes up-regulated among the SP of MM,
LUZP4, MAGEA12, MAGEA3, MAGEB2, MAGEB3, and
SSX2, have particular potential for consideration as targets
for immunotherapy targeting the myeloma stem cell-like
cells. These CTA genes are localized to the X-chromosome
(Table II). As shown by previous studies (Dakshinamurthy
et al, 2008), CTA genes localized to this chromosome are
highly immunogenic; in contrast, immunogenicity of CTA
localized on autosomal chromosomes has not been proven
(Scanlan et al, 2004).
It is worth noting that this study included 8 MM patients
(Tables SI, SII); however, it remains difficult to link CTA
gene expression profile to the different stages of MM. We
believe that more MM cases are required to shed the light on
this task.
Immunotherapy, targeting myeloma stem cell-like cells
expressing CTA, is particularly attractive for MM patients
who have achieved complete remission. The majority, if not
all, of these patients developed recurrent disease that is resis-
tant to multiple agents. It has been proposed that the mye-
loma stem cells, which are highly drug-resistant in nature
and have self-renewal capability, play a critical role in the
recurrence of MM. This immunotherapy approach is likely
to eradicate the myeloma stem cells in these patients to
ensure long-term remission of these patients. In our previous
studies, we have demonstrated the feasibility of this approach
and showed that cytotoxic T-cells (CTL) specific for PRAM-
E-derived peptide can target leukaemic and leukaemic-pre-
cursor cells expressing PRAME (Quintarelli et al, 2011).
Additionally, previous studies have suggested that some
CTA genes may function as regulators of cell-cycle progres-
sion, apoptosis and transcriptional repression (Scanlan et al,
2002; Yawata et al, 2010). CTA genes may thus participate in
maintaining the stem cell pool directly or indirectly. In the
present study, knock down LUZP4 expression with siRNA
reduced the colony-forming ability of MM cells and sensitized
the cells to chemotherapy. This finding will initiate further
investigation regarding the function of CTA genes in MM.
In summary, the current study identifies a subset of CTA
genes highly expressed by multiple myeloma stem cell-like
side population cells using a unique high throughput
Table II. Up-regulated cancer testis antigen (CTA) genes in bone
marrow from primary multiple myeloma patients. The up-regulated
CTA genes in the side population of each multiple myeloma patient,
as compared with mature plasma cells, is indicated by “↑”.
Gene Multiple myeloma cases
Symbol Location 1 2 3 4 5 6 7 8
AKAP4 Xp11.2 ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑
ANKRD45 1q25.1 ↑ ↑ ↑ ↑ ↑ ↑ ↑
AURKA 20q13 ↑ ↑ ↑ ↑ ↑
C4A 6p21.3 ↑ ↑ ↑ ↑ ↑
CFLAR 2q33–q34 ↑ ↑ ↑ ↑ ↑ ↑
CST3 20p11.21 ↑ ↑ ↑ ↑
DDX43 6q12-q13 ↑ ↑ ↑ ↑ ↑ ↑
ELOVL4 6q14 ↑ ↑ ↑ ↑ ↑
FANCI 15q26.1 ↑ ↑ ↑ ↑ ↑ ↑ ↑
HIST1H2BG 6p21.3 ↑ ↑ ↑ ↑ ↑
LUZP4 Xq23 ↑ ↑ ↑ ↑ ↑ ↑ ↑
MAGEA12 Xq28 ↑ ↑ ↑ ↑ ↑ ↑ ↑
MAGEA3 Xq28 ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑
MAGEB2 Xp21.3 ↑ ↑ ↑ ↑ ↑ ↑
MAGEB3 Xp21.3 ↑ ↑ ↑ ↑ ↑ ↑ ↑
PRAME 22q11.22 ↑ ↑ ↑ ↑ ↑ ↑
RRM2 2p25–p24 ↑ ↑ ↑ ↑ ↑ ↑ ↑
SSX2 Xp11.22 ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑
TEX14 17q22 ↑ ↑ ↑ ↑ ↑ ↑ ↑
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qRT-PCR assay designed in our laboratory. The resulting
data provides the framework for using immunotherapy to
target the myeloma stem cells expressing high levels of CTA
for the long-term cure of MM.
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Fig S1. Immunofluorescence membrane staining with
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Fig 5. LUZP4 is related with the colony-forming ability and drug resistance in MM cells. (A) LUZP4 expression in MM cell line U266 was
knocked down with siRNA and the efficiency was verified with Western blot. The experiments were repeated three times, and representative fig-
ures are shown. (B) Colony formation assay. 5 9 103 U266 knock down with LUZP4 siRNA or scrambled siRNA were resuspended in agar and
seeded in a 6-well plate. Complete medium was added on the top and changed twice a week. After 2 weeks, dishes were stained with methylene
blue, pictures were taken under a phase contrast microscope, and colony number was counted. Representative images are shown from indepen-
dent experiments (upper panel), and data are presented as mean  standard deviation of triplicate experiments (**P < 001, t-test) (lower panel).
(C) Apoptosis assay. U266 knock down with LUZP4 siRNA or scrambled siRNA were seeded in 6-well plate with complete medium. Cells were
treated with 40 nmol/l bortezomib (BZM) or 2 lmol/l arsenic trioxide (ATO) for 24 h followed with flow cytometric apoptosis assay. The
percentage of Annexin V/PI double-negative cells was noted. Experiments were repeated three times, and representative blots are shown.
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Fig S2. Up-regulated CTA genes in the ALDH high popu-
lation of MM cell line compared with ALDH low
population.
Table SI. MM patient information.
Table SII. Up-regulated CTA genes in SP of MM patient
BMs.
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